The goal of this study is to determine at what dose an experimental drug called ASP1012 is tolerated in people with locally advanced (spread to nearby areas) or metastatic (spread to distant parts) solid tumors that cannot be removed or have spread to other parts of the body. ASP1012 is a type of a virus that is designed to kill cancer cells and may help the patient’s own immune system to attack cancer cells. The drug has also been genetically changed so that it will preferentially grow in cancer cells rather than normal healthy cells. Participants will receive ASP1012 directly into their veins through an intravenous (IV) infusion.
What is the full name of this clinical trial?
1012-CL-0101: A Phase 1, Open-Label, Dose Escalation and Expansion Study of ASP1012, an Oncolytic Virus, in Participants with Locally Advanced or Metastatic Solid Tumors
Colon, Melanoma, Other Female Genital, Rectum
Wentzel, Kristopher
Cathie T Chung, Inderjit Mehmi, Justin Moyers, Navid Hafez, Omid Hamid, Vi K. Chiu
Adult
I
STUDY00003111
NCT06171178
Saba Mukarram
Colon, Melanoma, Other Female Genital, Rectum
Wentzel, Kristopher
Adult
I
1012-CL-0101
NCT06171178
Saba Mukarram